It was observed that HER2-positive breast cancer is associated with elevated CTC counts, whereas TNBC, despite lower CTC counts, exhibits CTCs and CTC clusters with enhanced invasiveness and metastatic potential due to Notch1 signaling pathway activation, elevated PD-L1 expression, and desialylation modifications. This evidence concerns the gene ERBB2 and breast cancer.